SEC Company Response from Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Apr 30, 2020

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: April 30, 2020 · CIK: 0001595097 · Accession: 0001493152-20-007445

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-237588

Date

April 30, 2020

Author

Chief

Form

CORRESP

Company

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)

Letter

Corbus Pharmaceuticals Holdings, Inc.

River Ridge Drive

Norwood, MA 02062

April 30, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Corbus Pharmaceuticals Holdings, Inc. (the “Company”)

Registration Statement on Form S-3, as amended (File No. 333-237588)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on May 1, 2020, or as soon as practicable thereafter.

Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

U.S. Securities and Exchange Commission

April 30, 2020

Page

Very
truly yours,
CORBUS
PHARMACEUTICALS

Show Raw Text

CORRESP
1
filename1.htm

Corbus
Pharmaceuticals Holdings, Inc.

500
River Ridge Drive

Norwood,
MA 02062

April
30, 2020

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

 Re: Corbus
                                         Pharmaceuticals Holdings, Inc. (the “Company”)

Registration
Statement on Form S-3, as amended (File No. 333-237588)

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration
Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m.,
Eastern Time, on May 1, 2020, or as soon as practicable thereafter.

Please
call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement
or with any questions.

[Signature
page follows.]

U.S.
Securities and Exchange Commission

April
30, 2020

Page
2

    Very
    truly yours,

    CORBUS
    PHARMACEUTICALS

    HOLDINGS,
    INC.

    By:
    /s/
    Sean Moran

    Name:
    Sean
    Moran

    Title:
    Chief
    Financial Officer

    -2-

SecProbe.io